https://www.biopharm.org.tw
+886-2-2655-8135
services@biopharm.org.twMain Products
Yoda Therapeutics Inc. is a biotechnology company advancing AI-driven drug development for CNS disorders. Our mission is to address unmet medical needs by offering innovative treatment options. Our flagship drug, YA-101, is an AI-modeled New Chemical Entity specifically designed to treat Multiple System Atrophy. YA-101 has shown significant therapeutic potential in animals and demonstrated a safety profile during Phase I trial in healthy adults. In 2022, it received Orphan Drug Designation (ODD) from the US FDA for MSA. Currently, YA-101 is undergoing Phase II trials in both the US and Taiwan.
Business Interests
Clinical Trial Collaboration
Contact Info
Da-Zhong Luo
Non-Clinical R&D Director
+886-952730761
dzluo@yodapharma.com